20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Relay Therapeutics Inc (RLAY) operates in the BIOTECHNOLOGY industry and is headquartered in Cambridge, United States with about 202 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, RLAY reported $15M in revenue and ($276M) in net income.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
Interactive charts & full statements → Open the RLAY valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $10M | $15M | $10M | $26M | $1M | $3M | $83M | $0M | $0M |
| Gross Profit | ($60M) | $12M | ($305M) | ($301M) | ($242M) | ($166M) | $79M | ($3M) | ($2M) |
| Gross Margin % | -600.0% | 76.8% | -3052.2% | -1177.6% | -17496.3% | -5492.2% | 95.7% | — | — |
| Operating Income (EBIT) | ($311M) | ($303M) | ($372M) | ($373M) | ($299M) | ($365M) | ($56M) | ($84M) | ($50M) |
| Operating Margin % | -3110.0% | -1971.6% | -3722.1% | -1460.1% | -21670.9% | -12040.2% | -67.5% | — | — |
| Net Income | ($286M) | ($276M) | ($338M) | ($342M) | ($291M) | ($364M) | ($52M) | ($67M) | ($49M) |
| Net Margin % | -2860.0% | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% | -63.4% | — | — |
| EBITDA | ($287M) | ($273M) | ($380M) | ($374M) | ($307M) | ($223M) | ($52M) | ($81M) | ($48M) |
| Earnings Per Share (EPS) | $-1.57 | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 | $-0.58 | $-15.53 | $-19.63 |
| Shares Outstanding (M) | 203M | 172M | 143M | 123M | 112M | 95M | — | 4M | 2M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $3M | $7M | $0M | $1M | $8M | $0M | $0M |
| Gross Profit | $0M | $2M | $6M | ($68M) | ($61M) | $8M | ($64M) | ($77M) |
| Gross Margin % | 100.0% | 83.2% | 91.4% | — | -8980.1% | 100.0% | — | — |
| Operating Income (EBIT) | ($91M) | ($79M) | ($61M) | ($80M) | ($77M) | ($85M) | ($85M) | ($96M) |
| Operating Margin % | -25949.7% | -2619.7% | -866.2% | — | -11351.1% | -1105.2% | — | — |
| Net Income | ($84M) | ($73M) | ($55M) | ($74M) | ($70M) | ($77M) | ($76M) | ($88M) |
| Net Margin % | -23916.3% | -2443.0% | -784.1% | — | -10395.1% | -1003.6% | — | — |
| EBITDA | ($83M) | ($73M) | ($58M) | ($73M) | ($69M) | ($76M) | ($75M) | ($87M) |
| Earnings Per Share (EPS) | $-0.41 | $-0.41 | $-0.32 | $-0.43 | $-0.41 | $-0.46 | $-0.45 | $-0.63 |
| Shares Outstanding (M) | 203M | 180M | 172M | 172M | 171M | 169M | 167M | 140M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($212M) | ($235M) | ($249M) | ($300M) | ($229M) | ($74M) | ($102M) | ($66M) | ($44M) |
| Capital Expenditures (CapEx) | $0M | $0M | $2M | $4M | $9M | $3M | $2M | $8M | $2M |
| Free Cash Flow (FCF) | ($212M) | ($236M) | ($251M) | ($304M) | ($239M) | ($78M) | ($104M) | ($74M) | ($46M) |
| FCF Margin % | -2120.0% | -1536.1% | -2509.5% | -1191.7% | -17273.9% | -2571.1% | -126.3% | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($54M) | ($51M) | ($45M) | ($62M) | ($55M) | ($73M) | ($58M) | ($75M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($54M) | ($51M) | ($45M) | ($62M) | ($55M) | ($74M) | ($58M) | ($75M) |
| FCF Margin % | -15459.7% | -1703.7% | -640.9% | — | -8166.5% | -958.4% | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $967M | $621M | $871M | $844M | $1.1B | $1.0B | $800M | $393M | $429M |
| Cash & Cash Equivalents | $121M | $84M | $124M | $144M | $152M | $280M | $448M | $42M | $422M |
| Total Liabilities | $77M | $54M | $94M | $92M | $150M | $111M | $37M | $574M | $540M |
| Total Debt (Short + Long-Term) | $4M | $4M | $6M | $5M | $4M | $2M | $2M | $1M | $0M |
| Total Shareholders' Equity | $890M | $567M | $778M | $752M | $950M | $898M | $763M | ($180M) | ($111M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RLAY viewer.
About TickerBase · Data methodology & sources · Privacy · Terms